{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:00:53Z","timestamp":1793138453600,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03259-8","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:44:46Z","timestamp":1750477486000},"page":"4300-4317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced\/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation"],"prefix":"10.1007","volume":"42","author":[{"given":"Divyan","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoora","family":"Moradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Obiozor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-409X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"3","key":"3259_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA A Cancer J Clin"},{"issue":"5","key":"3259_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065303","volume":"13","author":"A W\u00e9ber","year":"2023","unstructured":"W\u00e9ber A, Morgan E, Vignat J, et al. Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open. 2023;13(5):e065303.","journal-title":"BMJ Open"},{"key":"3259_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693.","journal-title":"Cancer Epidemiol"},{"key":"3259_CR4","unstructured":"American Cancer Society. What is lung cancer? 2019. https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html. Accessed Feb 11, 2021."},{"issue":"7689","key":"3259_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"key":"3259_CR6","unstructured":"American Cancer Society. Lung cancer survival rates. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed Jan 10, 2025."},{"issue":"14","key":"3259_CR7","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"key":"3259_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107293","volume":"184","author":"TKH Lim","year":"2023","unstructured":"Lim TKH, Skoulidis F, Kerr KM, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293.","journal-title":"Lung Cancer"},{"key":"3259_CR9","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc. Accessed Jan 9, 2025."},{"key":"3259_CR10","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc. Accessed Jan 9, 2025."},{"key":"3259_CR11","unstructured":"European Medicines Agency. Lumykras (sotorasib). 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lumykras. Accessed Jan 10, 2025."},{"key":"3259_CR12","unstructured":"European Medicines Agency. Krazati (adagrasib). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/krazati. Accessed Jan 10, 2025."},{"issue":"25","key":"3259_CR13","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"3259_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387(2):120\u201331.","journal-title":"N Engl J Med"},{"issue":"10","key":"3259_CR15","doi-asserted-by":"publisher","first-page":"S647","DOI":"10.1016\/j.jtho.2024.09.1221","volume":"19","author":"D Chopra","year":"2024","unstructured":"Chopra D, Waterhouse DM, Sylvester B, Jamotte A, Stollenwerk B. EP.12C.01 sotorasib vs adagrasib: matching-adjusted indirect comparison in prior treated KRAS G12C advanced non-small cell lung cancer. J Thorac Oncol. 2024;19(10):S647\u20138.","journal-title":"J Thorac Oncol"},{"issue":"10378","key":"3259_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase\u00a03 trial. Lancet. 2023;401(10378):733\u201346.","journal-title":"Lancet"},{"issue":"17","key":"3259_CR17","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","volume":"42","author":"TSK Mok","year":"2024","unstructured":"Mok TSK, Yao W, Duruisseaux M, et al. KRYSTAL-12: Phase\u00a03 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. J Clin Oncol. 2024;42(17):8509.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3259_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"12","key":"3259_CR19","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/cancers12123648","volume":"12","author":"B Halmos","year":"2020","unstructured":"Halmos B, Burke T, Kalyvas C, et al. A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS \u22651% metastatic NSCLC. Cancers. 2020;12(12):3648.","journal-title":"Cancers"},{"issue":"4","key":"3259_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/03007995.2018.1520696","volume":"35","author":"K Reckamp","year":"2019","unstructured":"Reckamp K, Lin HM, Huang J, et al. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Curr Med Res Opin. 2019;35(4):569\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3259_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2217\/cer-2020-0063","volume":"9","author":"P Chu","year":"2020","unstructured":"Chu P, Antoniou M, Bhutani MK, Aziez A, Daigl M. Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer. J Comp Eff Res. 2020;9(12): 861\u201376.","journal-title":"J Comp Eff Res"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall'Olio","year":"2020","unstructured":"Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95\u2013104.","journal-title":"Lung Cancer"},{"issue":"8","key":"3259_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12534","volume":"3","author":"F Yang","year":"2020","unstructured":"Yang F, Markovic SN, Molina JR et al. Association of sex, age, and Eastern Cooperative Oncology Group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(8):e2012534.","journal-title":"JAMA Netw Open"},{"issue":"17","key":"3259_CR24","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9016","volume":"41","author":"AMC Dingemans","year":"2023","unstructured":"Dingemans AMC, Syrigos K, Livi L et al. Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase\u00a03, randomized, controlled trial (RCT). J Clin Oncol. 2023;41(17):9016.","journal-title":"J Clin Oncol"},{"key":"3259_CR25","doi-asserted-by":"publisher","first-page":"S1247","DOI":"10.1016\/j.annonc.2024.08.2299","volume":"35","author":"F Barlesi","year":"2024","unstructured":"Barlesi F, Yao W, Duruisseaux M et al. LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): results from KRYSTAL-12. Ann Oncol. 2024;35:S1247\u20138.","journal-title":"Ann Oncol"},{"key":"3259_CR26","unstructured":"Mitchell M, Muftakhidinov B, Winchen T. Engauge Digitizer Software. 2023. http:\/\/markummitchell.github.io\/engauge-digitizer. Accessed 9 Jan 2025."},{"key":"3259_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3259_CR28","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016."},{"key":"3259_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00621","volume":"7","author":"G Lamberti","year":"2023","unstructured":"Lamberti G, Aizer A, Ricciuti B et al. Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRAS(G12C)-mutant non-small-cell lung cancer. JCO Precis Oncol. 2023;7:e2200621.","journal-title":"JCO Precis Oncol"},{"key":"3259_CR30","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna. Austria. Austria: R Foundation for Statistical Computing. 2010."},{"issue":"5","key":"3259_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.21037\/tlcr-23-97","volume":"12","author":"Y Oya","year":"2023","unstructured":"Oya Y, Mitsudomi T. Is adagrasib just another sotorasib?\u2014or, should we differentiate their usage according to patients\u2019 clinical presentation? Transl Lung Cancer Res. 2023;12(5):940\u20133.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"3259_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/10600280231197459","volume":"58","author":"N Mausey","year":"2024","unstructured":"Mausey N, Halford Z. Targeted therapies for previously \u201cundruggable\u201d KRAS-mutated non-small cell lung cancer: a review of sotorasib and adagrasib. Ann Pharmacother. 2024;58(6):622\u201335.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3259_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jval.2022.07.002","volume":"26","author":"S Smith","year":"2023","unstructured":"Smith S, Albuquerque de Almeida A, Ines M, Iadeluca L, Cooper M. Matching-adjusted indirect comparisons of lorlatinib versus chemotherapy for patients with second-line or later anaplastic lymphoma kinase-positive non-small cell lung cancer. Value Health. 2023;26(1):64\u201370.","journal-title":"Value Health"},{"issue":"12","key":"3259_CR34","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jval.2023.09.167","volume":"26","author":"W Bouwmeester","year":"2023","unstructured":"Bouwmeester W, Laurie M, Korytowsky B, et al. CO95 matching-adjusted indirect comparison (MAIC) in previously treated KRAS G12C-mutated advanced\/metastatic non-small cell lung cancer (a\/mNSCLC): adagrasib versus sotorasib. Value Health. 2023;26(12):S31.","journal-title":"Value Health"},{"issue":"6","key":"3259_CR35","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jval.2024.03.170","volume":"27","author":"D Maciel","year":"2024","unstructured":"Maciel D, Bouwmeester W, Korytowsky B, et al. CO82 Bayesian pan-tumor multilevel meta-regression: an unanchored indirect treatment comparison (ITC) of adagrasib versus sotorasib in previously treated KRASG12C-mutated advanced\/metastatic solid tumors. Value Health. 2024;27(6):S32.","journal-title":"Value Health"},{"key":"3259_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107966","volume":"196","author":"M Chen","year":"2024","unstructured":"Chen M, Huang Y, Jiang S, Ke C. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse event reporting system (FAERS) database: a real-world pharmacovigilance study. Lung Cancer. 2024;196:107966.","journal-title":"Lung Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03259-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:17:05Z","timestamp":1757193425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03259-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Divyan Chopra, Nadia Karim, Cynthia Obiozor, and Bj\u00f6rn Stollenwerk are employees of and stockholders in Amgen. Hoora Moradian is an employee of Cytel that received consultancy fees from Amgen. Zhiyi Lan was employed by Cytel, Inc., at the time of study conduct. J\u00fcrgen Wolf received advisory board and lecture fees from AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Chugai, Daiichi Sankyo, Ellipses Pharma, Genmab, Janssen, Lilly, Loxo, Merck, Murati, Merck Sharp & Dohme (MSD), Novartis, Novalent, Pfizer, Pierre-Fabre, Regeneron, Roche, Seattle Genetics, Takeda, and Turning Point as well as research support from AstraZeneca, BMS, Janssen Pharmaceutica, Novartis, and Pfizer. David M. Waterhouse has served in a consulting or advisory role for BMS, AZTherapies, AbbVie, Amgen, McGivenny Global, Janssen Oncology, Seattle Genetics, Exelixis, Eisai, EMD Serono, Merck, Pfizer, Mirati Therapeutics, Regeneron\/Sanofi, Fresenius KBI, Lilly, Sanofi, Astellas Pharma, Gilead Sciences, Takeda, Daiichi Sankyo, Novartis, Bayer, AVEO; has participated in speakers\u2019 bureaus for BMS, Janssen Oncology, Merck, AstraZeneca, Amgen, and EMD Serono; has received travel, accommodations, expenses from BMS. Enriqueta Felip has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, Iteos Therapeutics, Janssen, Johnson & Johnson, MSD, Novartis, Pierre-Fabre, Pfizer, Regeneron, and Turning Point; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, MSD, Novartis, Peervoice, Pfizer, and Regeneron; has received support for attending meetings and\/or travel from AstraZeneca, Janssen, and Roche; is an independent member of the board of Grifols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Zhiyi Lan was employed by Cytel, Inc. at the time of study conduct. Zhiyi\u2019s current affiliation\u00a0is IQVIA Inc., CA, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.The CodeBreak 200 trial used in the study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The protocol and amendments were approved by the institutional review board at each participating site and regulatory authorities of participating countries. The protocol for the KRYSTAL-12 trial states that the study will be conducted in accordance with International Ethical Guidelines for Biomedical Research Involving Human Patients (Council for International Organizations of Medical Sciences 2002), Guidelines for Good Clinical Practice (GCP) (International Council for Harmonisation [ICH] 1996), ICH E6 (R2) and concepts that have their origin in the Declaration of Helsinki (World Medical Association 1996, 2008 & 2013), the study will be conducted under a protocol reviewed and approved by an institutional review board\/ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}